NCT02238314已完成2 期
Tipranavir Disodium: An Open-Label ExploratorySstudy of Tipranavir and Ritonavir in Combination With One Nucleoside Reverse Transcriptase Inhibitor and One Non-Nucleoside Reverse Transcriptase Inhibitor in Multiple Protease Inhibitor-Experienced HIV Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 41
- 主要终点
- Change from baseline in HIV-1 RNA concentrations
研究概览
简要总结
The primary objective was to evaluate the antiviral activity and safety of two regimens of tipranavir (500 mg BID or 1000 mg BID) plus ritonavir (100 mg BID) administered in combination with 1 new nucleoside reverse transcriptase inhibitor (NRTI) + efavirenz in multiple protease-inhibitor-experienced HIV-1 positive patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Multiple (two or more) PI-experience. Eligible patients must have had exposure to at least two antiretroviral regimens containing a single protease inhibitor or a regimen containing dual protease inhibitors
- •In the investigator's opinion, the patient had adhered to PI-containing regimens
- •Exposure of ≥ 3 months to the current PI therapy
- •Exposure of ≥ 4 months to the prior PI therapy with single PI-containing regimens
- •Stable PI-containing regimen for at least 2 months prior to study entry
- •HIV-1-RNA ≥ 5,000 copies/mL
- •Cluster of differentiation (CD)4+ cell count ≥ 50 cells/mm**3
- •At least one new NRTI option available
- •Age ≥ 13 years
- •Acceptable screening laboratory values that indicated adequate baseline organ function at the time of screening. Laboratory values were considered acceptable if the severity was ≤ Grade 1 (AIDS Clinical Trial Group (ACTG) Grading Scale). Stable Grade 2 abnormalities were permitted if the values had been demonstrated and documented for at least ≥ 2 months.
- •Acceptable medical history, physical examination, electrocardiogram, and chest X-ray prior to entry into the treatment phase of the study
- •Agreement to use a barrier contraceptive method of birth control for at least 30 days prior to study drug administration, during the study, and 30 days after the end of the study
- •Ability to swallow numerous tablets and capsules without difficulty
- •Ability to understand and provide informed consent. Minors were required to have approval of a parent or legal guardian
排除标准
- •Prior exposure, defined as > 7 treatment days, to nonnucleoside reverse transcriptase inhibitor (NNRTIs) including, but not limited to: nevirapine, efavirenz, delavirdine, atevirdine, MKC-442, loviride, and HBY-097
- •Clinically significant active or acute (onset within the month previous to study entry) medical problems, including the following: opportunistic infections, such as active cryptococcosis, Pneumocystis carinii pneumonia, herpes zoster, histoplasmosis, or cytomegalovirus or nonopportunistic diseases, including, but not limited to, progressive multifocal leukoencephalopathy, lymphoma, or malignancy requiring systemic therapy
- •Prior exposure (> 7 days) to tipranavir
- •History of clinically significant nervous system or muscle diseases, seizure disorder, or psychiatric disorder that might impair adherence to the protocol
- •Taking of any known P450 3A enzyme-inducing drugs within 30 days of study entry and including the following: rifabutin, rifampin, carbamazepine, dexamethasone, phenobarbital, phenytoin, sulfadimidine, sulfinpyrazone, or troleandomycin
- •Hypersensitivity to tipranavir and/or ritonavir
- •Use of interferons, interleukins, HIV vaccines, or any active immunizations within 30 days prior to study entry
- •Taking of any investigational medication with the exception of adefovir dipivoxil (Preveon™) and amprenavir (Agenerase™) within 30 days of study entry
- •Pregnancy or lactation (serum β-human chorionic gonadotrophin test had to have been negative within 14 days of study entry)
- •Evidence of active substance abuse, which in the investigator's opinion, could affect compliance to the protocol
- •In the investigator's judgment, inability to comply with the protocol requirements for reasons other than those specified
研究组 & 干预措施
Tipranavir high dose
Experimental
干预措施: Ritonavir (Drug)
Tipranavir low dose
Experimental
干预措施: Tipranavir low dose (Drug)
Tipranavir low dose
Experimental
干预措施: Ritonavir (Drug)
Tipranavir low dose
Experimental
干预措施: Nucleoside Reverse Transcriptase Inhibitor (NRTI) (Drug)
Tipranavir low dose
Experimental
干预措施: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) (Drug)
Tipranavir high dose
Experimental
干预措施: Tipranavir high dose (Drug)
Tipranavir high dose
Experimental
干预措施: Nucleoside Reverse Transcriptase Inhibitor (NRTI) (Drug)
Tipranavir high dose
Experimental
干预措施: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) (Drug)
结局指标
主要结局
Change from baseline in HIV-1 RNA concentrations
时间窗: weeks 16, 24, 48 and 80
Occurrence of HIV-1 RNA levels below the limit of quantitation (BLQ) (400 copies/mL)
时间窗: up to 112 weeks
measured by the Roche Amplicor HIV-1 Monitor™ polymerase chain reaction (PCR) Method
Occurrence of HIV-1 RNA levels BLQ (50 copies/mL)
时间窗: up to 112 weeks
measured by the Roche Amplicor UltraSensitive™ PCR Method
Number of patients with treatment-emergent and drug-related adverse events (AEs)
时间窗: up to 115 weeks
Number of patients with serious adverse events (SAEs)
时间窗: up to 115 weeks
Number of patients with grade 3 and 4 laboratory abnormalities
时间窗: up to 115 weeks
次要结局
- Change from baseline in cluster of differentiation (CD) 4+ cell count responses(weeks 24, 48 and 80)
- Change from baseline in CD8+ cell count responses(weeks 24, 48 and 80)
- Time to new or recurring AIDS-defining illness(up to 115 weeks)
- Time to new or recurring HIV-related illness(up to 115 weeks)
- Time to death(up to 115 weeks)
- Occurrence of AIDS-defining illness,(up to 115 weeks)
- Occurrence of HIV-related illness,(up to 115 weeks)
- Occurrence of death(up to 115 weeks)
- Time to virologic failure(up to 115 weeks)
- Change from baseline in cholesterol(up to 115 weeks)
- Change from baseline in HDL(up to 115 weeks)
- Change from baseline in triglycerides(up to 115 weeks)
- Change from baseline in blood glucose(up to 115 weeks)
- Steady-state plasma concentrations(up to week 24)
- Fold-change in concentration required to produce 50% of inhibition (IC 50)(Baseline, weeks 24, 48 and 80)
研究者
相似试验
终止
2 期
Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 PatientsHIV InfectionsNCT02239835Boehringer Ingelheim79
已完成
3 期
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)HIV InfectionsNCT00144170Boehringer Ingelheim882
已完成
1 期
Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected ChildrenHIV InfectionsNCT00076999Boehringer Ingelheim115
终止
3 期
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PIHIV InfectionsNCT00517192Boehringer Ingelheim40
Approved For Marketing
不适用
Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV InfectionHIV InfectionsNCT00062660Boehringer Ingelheim